Palatin’s PL9588 shows positive efficacy results in glaucoma

Palatin (PTN) announced new preclinical data for PL9588, a novel melanocortin receptor agonist, presented at the 2025 Association for Research in Vision and Ophthalmology Annual Meeting. The findings support the potential of PL9588 as a topical treatment for glaucoma, combining both IOP-lowering and neuroprotective effects. Key preclinical findings for PL9588 include: reduces intraocular pressure via aqueous outflow mechanism; increased fluid movement through the trabecular meshwork; provides retinal neuroprotection independent of IOP lowering; reduced retinal cell stress/death by ~25% in damaged retinas; decreased retinal ganglion cell death in an ischemia/reperfusion model; supports dual-action in glaucoma; combines pressure reduction and neuronal protection; clear mechanism of action supports further development. Palatin believes that these findings position PL9588 as a potential next-generation candidate in the evolving landscape of glaucoma therapeutics.